Here's why the Mesoblast (ASX:MSB) share price is sinking today

This comes after the release of it's respiratory function results earlier.

The Mesoblast Limited (ASX: MSB) share price has sunk more than 4% in today's trading session.

Shares in the biotechnology company are struggling today after Mesoblast released an announcement earlier today.

Let's take a look at what Mesoblast announced and why investors are jumping off.

Scientists in a laboratory look at a computer screen with anticipation on their faces.

Image source: Getty Images

What's driving the Mesoblast share price lower

Earlier today, Mesoblast released respiratory function results from its COVID-19 trial.

The clinical results relate to Mesoblast's randomized controlled trial of its remestemcel-L product on ventilator dependent COVID-19 patients. These patients have also been diagnosed with acute respiratory distress syndrome (ARDS).

Mesoblast reported that remestemcel-L improved respiratory function in patients under 65 years old. In patients older than 65 years old, Mesoblast noted that remestemcel-L improved respiratory function at day 7.

Other secondary outcome results indicated that patients under 65 who received dexamethasone in addition to remestemcel-L reported improved respiratory function.

Mesoblast noted that the company has entered into a license and collaboration agreement with pharmaceutical giant Novartis. The agreement involved the development, manufacture, and commercialisation of remestemcel-L.

The company noted that the commercialisation of remestemcel-L will initially focus on the treatment of ARDS.

However, Mesoblast noted that the agreement remains subject to certain conditions, including analysis of results from the COVID-19 ARDS trial.

Although the announcement was marked 'non-sensitive', investors don't seem too impressed by the results. Clinical outcomes were also presented by Mesoblast Chief Executive Officer, Dr Silviu Itescu at the Pulmonary Disease Conference.

Snapshot of the Mesoblast share price

Mesoblast is a world leader in developing regenerative medicines for inflammatory diseases.

The company was a favourite among retail investors last year after it announced promising results for its remestemcel-L treatment for COVID-19.

After the initial euphoria which saw the Mesoblast share price hit a six-year peak in September last year, shares in the biotech have struggled. Shares in Mesoblast are trading more than 60% lower from their September highs.

As a result, Mesoblast has been one of the worst performers among healthcare companies on the S&P/ASX 200 Index (ASX: XJO) in FY21.

The Mesoblast share price has been plagued by various registration issues and has faced multiple class actions in the US.

At the time of writing, the Mesoblast share price is trading around 4% lower for the day, near its intra-day low of $1.89.

Motley Fool contributor Nikhil Gangaram has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ASX Share Market News

Happy wife holding her hands on her husband's shoulders while both look at a laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

A man stands in front of a chart with an arrow going down and slaps his forehead in frustration.
ASX Share Market News

ASX 200 mining shares smashed in major market sell-off

The ASX 200 fell 5.39% amid a mining sell-off, with BHP shares tumbling almost 13% last week.

Read more »

A woman weraing a stripy t-shirt winks as she points to the decorative gold crown on her head.
ASX Share Market News

CBA shares back on top of the ASX 200 as BHP dives 13% this week

CBA shares have rallied 9.5% over the past month whilst BHP tumbled 13% this week.

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

IPO spelt out on a laptop with a red and green bar chart underneath.
IPOs

Anthropic hits the market. Was it enough to distract investors from a bruised AI sector and Nvidia's scandal?

Was the biggest IPO in US history enough to re-energise the AI trade?

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »